CD34 and myelodysplastic syndrome: This notion is supported by recent findings where activation of the NF-κB pathway in CD34+ HSPCs is implicated in MDS pathogenesis [14] and CD271+ mesenchymal cells co-localize with CD34+ HSPCs in the bone marrow section of MDS patients [9].